ASP Isotopes Inc. (W62)
XFRA 
Summary
W62 Chart
Helium supply shock highlights fragile global market, D3 Energy CEO says
A fresh squeeze in global helium markets is sending prices sharply higher and exposing just how fragile the supply chain for the critical industrial gas has...
ASP Isotopes Q3 Earnings Preview: Active Quarter, But Too Much Uncertainty
ASP Isotopes is transitioning to a revenue stage, but remains speculative, with Q3 results pending and limited current operations. ASPI's recent shipments of Ytterbium-176 and Silicon-28 could unlock $50–$70 million in potential revenues for 2026–2027, pending contract wins. The Renergen acquisition aims to cut enrichment costs by 96% and drive significant EBITDA growth by 2030, but execution risk remains.
ASP Isotopes Could Be The Next Big Nuclear Play
AI-driven demand for reliable power is fueling a nuclear renaissance, with Google and tech giants investing heavily in next-gen reactor infrastructure. ASP Isotopes stands out for its isotope enrichment technology, strategic TerraPower partnership, and expansion into advanced materials like Silicon-28. ASPI is a high-risk, high-reward pre-revenue play, with strong cash reserves but significant losses and premium valuation metrics reflecting future growth expectations.
ASP Isotopes Inc. (W62) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has ASP Isotopes Inc. ever had a stock split?
ASP Isotopes Inc. Profile
| Chemicals Industry | Materials Sector | Paul Elliot Mann CEO | XFRA Exchange | US00218A1051 ISIN |
| US Country | 271 Employees | - Last Dividend | - Last Split | 10 Nov 2022 IPO Date |
Overview
ASP Isotopes Inc. is a development stage advanced materials company established in 2021, based in Washington, District Of Columbia. The company specializes in the production, distribution, marketing, and sale of isotopes. At the forefront of its operations, ASP Isotopes Inc. is dedicated to the innovation and commercialization of essential isotopes for various industries, including the medical sector. It focuses on leveraging cutting-edge Quantum Enrichment technology to produce a range of isotopes, asserting itself as a pivotal player in the advanced materials industry.
Products and Services
- Molybdenum-100:
ASP Isotopes Inc. engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope. This particular isotope is primarily aimed at the medical industry, where it is used in various applications, indicating the company's contribution to healthcare advancements.
- Carbon-14:
Aside from Molybdenum-100, the company also focuses on the production of Carbon-14. This isotope has widespread uses, including in biomedical research, environmental science, and radiocarbon dating, showcasing ASP Isotopes Inc.'s commitment to supporting scientific research and development.
- Silicon-28:
Silicon-28 is another key product of ASP Isotopes Inc., underlining the company’s versatility in producing isotopes for varied applications. While the specific uses of Silicon-28 by the company are not detailed, Silicon-28 has significant potential in electronics and quantum computing, sectors which demand ultra-pure materials for innovation.
- Developing Isotopes with Quantum Enrichment Technology:
The company is at the forefront of developing Quantum Enrichment technology to produce a range of isotopes, including Ytterbium-176, Nickel-64, Lithium 6, Lithium 7, and Uranium-235. This innovative approach highlights ASP Isotopes Inc.’s role in advancing the technology used for isotope production, aiming to serve various sectors including medical, industrial, and energy, by providing high-purity isotopes crucial for diverse applications.
